These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

844 related items for PubMed ID: 11772142

  • 1. Rabeprazole: an update of its use in acid-related disorders.
    Carswell CI, Goa KL.
    Drugs; 2001; 61(15):2327-56. PubMed ID: 11772142
    [Abstract] [Full Text] [Related]

  • 2. Rabeprazole: a review of its use in acid-related gastrointestinal disorders.
    Langtry HD, Markham A.
    Drugs; 1999 Oct; 58(4):725-42. PubMed ID: 10551440
    [Abstract] [Full Text] [Related]

  • 3. Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders.
    Cheer SM, Prakash A, Faulds D, Lamb HM.
    Drugs; 2003 Oct; 63(1):101-33. PubMed ID: 12487624
    [Abstract] [Full Text] [Related]

  • 4. Lansoprazole: an update of its place in the management of acid-related disorders.
    Matheson AJ, Jarvis B.
    Drugs; 2001 Oct; 61(12):1801-33. PubMed ID: 11693467
    [Abstract] [Full Text] [Related]

  • 5. Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders.
    Fitton A, Wiseman L.
    Drugs; 1996 Mar; 51(3):460-82. PubMed ID: 8882382
    [Abstract] [Full Text] [Related]

  • 6. Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders.
    Langtry HD, Wilde MI.
    Drugs; 1997 Sep; 54(3):473-500. PubMed ID: 9279507
    [Abstract] [Full Text] [Related]

  • 7. Omeprazole. A review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs.
    Langtry HD, Wilde MI.
    Drugs; 1998 Sep; 56(3):447-86. PubMed ID: 9777317
    [Abstract] [Full Text] [Related]

  • 8. Esomeprazole: a review of its use in the management of gastric acid-related diseases in adults.
    McKeage K, Blick SK, Croxtall JD, Lyseng-Williamson KA, Keating GM.
    Drugs; 2008 Sep; 68(11):1571-607. PubMed ID: 18627213
    [Abstract] [Full Text] [Related]

  • 9. Esomeprazole: a review of its use in the management of acid-related disorders in the US.
    Scott LJ, Dunn CJ, Mallarkey G, Sharpe M.
    Drugs; 2002 Sep; 62(7):1091-118. PubMed ID: 11985491
    [Abstract] [Full Text] [Related]

  • 10. Rabeprazole.
    Prakash A, Faulds D.
    Drugs; 1998 Feb; 55(2):261-7; discussion 268. PubMed ID: 9506245
    [Abstract] [Full Text] [Related]

  • 11. Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders.
    Barradell LB, Faulds D, McTavish D.
    Drugs; 1992 Aug; 44(2):225-50. PubMed ID: 1382017
    [Abstract] [Full Text] [Related]

  • 12. Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group.
    Cloud ML, Enas N, Humphries TJ, Bassion S.
    Dig Dis Sci; 1998 May; 43(5):993-1000. PubMed ID: 9590413
    [Abstract] [Full Text] [Related]

  • 13. Comparison of rabeprazole-based four- and seven-day triple therapy and omeprazole-based seven-day triple therapy for Helicobacter pylori infection in patients with peptic ulcer.
    Yang KC, Wang GM, Chen JH, Chen TJ, Lee SC.
    J Formos Med Assoc; 2003 Dec; 102(12):857-62. PubMed ID: 14976565
    [Abstract] [Full Text] [Related]

  • 14. Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders.
    Spencer CM, Faulds D.
    Drugs; 1994 Sep; 48(3):404-30. PubMed ID: 7527761
    [Abstract] [Full Text] [Related]

  • 15. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials.
    Caro JJ, Salas M, Ward A.
    Clin Ther; 2001 Jul; 23(7):998-1017. PubMed ID: 11519776
    [Abstract] [Full Text] [Related]

  • 16. The benefit/risk profile of rabeprazole, a new proton-pump inhibitor.
    Johnson D, Perdomo C, Barth J, Jokubaitis L.
    Eur J Gastroenterol Hepatol; 2000 Jul; 12(7):799-806. PubMed ID: 10929909
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of rabeprazole once daily for acid-related disorders.
    Lanza F, Bardhan KD, Perdomo C, Niecestro R, Barth J.
    Dig Dis Sci; 2001 Mar; 46(3):587-96. PubMed ID: 11318537
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection in relation to CYP2C19 genotype.
    Lee SB, Park SJ, Ryu JK, Lee JK, Kim HJ, Bae JS, Jung HS, Park SM.
    Korean J Gastroenterol; 2003 Dec; 42(6):468-75. PubMed ID: 14695703
    [Abstract] [Full Text] [Related]

  • 19. Safety and efficacy of 7-day rabeprazole- and omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with documented peptic ulcer disease.
    Hawkey CJ, Atherton JC, Treichel HC, Thjodleifsson B, Ravic M.
    Aliment Pharmacol Ther; 2003 Apr; 17(8):1065-74. PubMed ID: 12694089
    [Abstract] [Full Text] [Related]

  • 20. Lansoprazole: pharmacokinetics, pharmacodynamics and clinical uses.
    Gremse DA.
    Expert Opin Pharmacother; 2001 Oct; 2(10):1663-70. PubMed ID: 11825309
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.